血府逐瘀胶囊联合硫酸氢氯吡格雷片治疗气虚血瘀型冠心病心绞痛临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R541.4

基金项目:


Clinical Study on Xuefu Zhuyu Capsules Combined with Clopidogrel Bisulfate Tablets for Angina Pectoris of Coronary Heart Disease of Qi Deficiency and Blood Stasis Type
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察血府逐瘀胶囊联合硫酸氢氯吡格雷片治疗气虚血瘀型冠心病心绞痛(CHDA) 的临床 疗效。方法:将90 例气虚血瘀型CHDA 患者按照随机数字表法分为对照组与治疗组各45 例。对照组采取硫 酸氢氯吡格雷片治疗,治疗组在对照组的基础上联合血府逐瘀胶囊治疗。比较2 组治疗前后心功能指标[左室 射血分数(LVEF)、每搏输出量(SV)、心脏指数(CI)]、血管内皮功能指标[内皮素(ET)、一氧化 氮(NO)、肱动脉血管舒张功能(FMD)] 水平变化,记录心绞痛发作次数、硝酸甘油用量与西雅图心绞 痛(SAQ) 评分,分析其临床疗效和不良反应情况。结果:治疗组总有效率为95.56%,对照组为80.00%, 2 组比较,差异有统计学意义(P<0.05)。治疗前,2 组LVEF、SV、CI 水平比较,差异无统计学意义(P> 0.05);治疗后,2 组上述3 项心功能指标均较治疗前升高(P<0.05),且治疗组各项指标均高于对照组(P< 0.05)。治疗前,2 组ET、NO、FMD 水平比较,差异无统计学意义(P>0.05)。治疗后,2 组ET 水平较治疗 前降低(P<0.05),NO、FMD 水平较治疗前升高(P<0.05);且治疗组各上述血管内皮功能指标改善均优于 对照组(P<0.05)。治疗前,2 组心绞痛发作次数、硝酸甘油用量及SAQ 评分比较,差异无统计学意义(P> 0.05)。治疗后,2 组心绞痛发作次数、硝酸甘油用量均较治疗前减少(P<0.05),SAQ 评分较治疗前升 高(P<0.05);且治疗组上述各项指标改善较对照组更显著(P<0.05)。治疗期间,治疗组不良反应发生率为 4.44%,对照组为17.78%,2 组比较,差异有统计学意义(P<0.05)。结论:血府逐瘀胶囊联合硫酸氢氯吡格 雷片治疗气虚血瘀型CHDA 疗效肯定,可有效改善患者心绞痛症状,提高心功能和血管内皮功能,且安全性 良好。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Xuefu Zhuyu Capsules combined with Clopidogrel Bisulfate Tablets for angina pectoris of coronary heart disease (CHDA) of qi deficiency and blood stasis type. Methods:A total of 90 cases of CHDA patients of qi deficiency and blood stasis type were divided into the control group and the treatment group according to the random number table method, with 45 cases in each group. The control group was treated with Clopidogrel Bisulfate Tablets,and the treatment group was additionally treated with Xuefu Zhuyu Capsules based on the treatment of the control group. Before and after treatment, the changes in levels of heart function indexes [left ventricular ejection fraction (LVEF), stroke volume (SV) and cardiac index (CI)],and vascular endothelial function [endothelin (ET),nitric oxide (NO) and brachial arterial flow-mediated dilation (FMD)] were compared between the two groups. The onset frequency of angina pectoris,nitroglycerin dosage and scores of Seattle Angina Questionnaire (SAQ) were recorded. The clinical effects and adverse reactions were analyzed. Results: The total effective rate was 95.56% in the treatment group and 80.00% in the control group,the difference being significant (P<0.05). Before treatment,there was no significant difference being found in the comparison of levels of LVEF,SV and CI between the two groups (P>0.05). After treatment,the above 3 heart function indexes in the two groups were increased when compared with those before treatment (P<0.05), and the indexes in the treatment group were higher than those in the control group (P<0.05). Before treatment, there was no significant difference being found in the comparison of levels of ET, NO and FMD between the two groups (P>0.05). After treatment,the ET level in the two group was decreased when compared with that before treatment (P<0.05), and the levels of NO and FMD were increased when compared with those before treatment (P<0.05);the improvement of the above indexes of vascular endothelial function in the treatment group was better than that in the control group (P<0.05). Before treatment, there was no significant difference being found in the comparison of onset frequency of angina pectoris, nitroglycerin dosage and SAQ scores between the two groups (P>0.05). After treatment,the onset frequency of angina pectoris and nitroglycerin dosage in the two groups were decreased when compared with those before treatment (P<0.05), and SAQ scores were increased when compared with those before treatment (P< 0.05);the improvement of the above indexes in the treatment group was more significant than that in the control group (P<0.05). During treatment,the incidence of adverse reactions was 4.44% in the treatment group and 17.78% in the control group,the difference being significant between the two groups (P<0.05). Conclusion: Xuefu Zhuyu Capsules combined with Clopidogrel Bisulfate Tablets has a definite effect on CHDA of qi deficiency and blood stasis type, which can effectively improve the symptoms of angina pectoris in pationts and enhance heart function and vascular endothelial function,with good safety.

    参考文献
    相似文献
    引证文献
引用本文

张浩,王李伟,刘庆宪.血府逐瘀胶囊联合硫酸氢氯吡格雷片治疗气虚血瘀型冠心病心绞痛临床研究[J].新中医,2023,55(8):33-37

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-04-25
  • 出版日期: